Abstract2026
The Role of Real-World Evidence in Supporting HTA and Reimbursement Decisions: Perspectives from Selected MENA Countries
Disease area: HTA & Real-World Evidence • ISPOR UAE Chapter Day — Oct 2026
HTAReimbursementStakeholder Interviews
Mixed-methods study of how RWE feeds HTA and reimbursement in KSA, UAE and Lebanon; UAE most advanced, with data fragmentation and HEOR capacity the main barriers.
Abstract2026
Quality-Adjusted Life-Year Results from a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Payer Perspective in the United Arab Emirates
Disease area: Multiple Myeloma • ISPOR UAE Chapter 2026 Conference, Rosewood Abu Dhabi — Jan 2026
QALYsDREAMM-7Payer Perspective
Localized partitioned survival model for Abu Dhabi: BVd delivered the highest QALYs (6.8) and life years (9.6) versus six second-line comparators.
Poster2025
A Systematic Review and Meta-Analysis of the Burdens of Vitiligo in the MENA Region
Disease area: Vitiligo • ISPOR-UAE Chapter Day, Abu Dhabi — Sep 2025
PrevalenceComorbiditiesQuality of Life
PRISMA-based SLR & meta-analysis across MENA; significant QoL impact (DLQI), with depression, thyroid, hypertension, renal disease, and diabetes burdens quantified.
Poster2025
A Systematic Review and Meta-Analysis on Impact of Alopecia Areata in MENA
Disease area: Alopecia Areata • ISPOR-UAE Chapter Day, Abu Dhabi — Sep 2025
PrevalenceComorbiditiesQuality of Life
PRISMA-based SLR & meta-analysis across MENA; high QoL burden and notable comorbidities (depression, anxiety, thyroid, diabetes), with KSA prevalence highlighted.
Abstract2025
Cost-Effectiveness Analysis of a Community Pharmacist-Based Intervention to Prevent Cardiovascular Complications in Patients with Type 2 Diabetes in Iran
Disease area: Type 2 Diabetes • ISPOR-UAE Chapter Day, Abu Dhabi — Sep 2025
Community PharmacyCost-EffectivenessCV Risk
12-month pharmacist-led programme improved HbA1c, lipids and SBP; Markov model shows cost savings of USD 1,469 with 0.045 life years gained.
Abstract2025
Evaluation of the Prophylactic Effect of Nigella sativa on Radiation-Induced Dermatitis in Breast Cancer Patients
Disease area: Breast Cancer • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
RadiotherapySupportive CareRandomized
Randomized study of topical vs oral Nigella sativa oil: grade ≥2 dermatitis fell to 25% and 32.6% vs 73.4% in controls, with no significant side effects.
Abstract2025
Optimizing Elective PCI: A Strategic Evaluation of Clopidogrel Brand Versus Generic Approaches
Disease area: Cardiovascular • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
GenericsAntiplateletTherapeutic Equivalence
Randomized, single-blind study of 115 elective-PCI patients: brand clopidogrel inhibited platelet aggregation more than two generics at 6 hours.
Abstract2025
Cost-Effectiveness Analysis of Isavuconazole Versus Liposomal Amphotericin for the Treatment of Invasive Mucormycosis in United Arab Emirates
Disease area: Invasive Fungal Infections • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
Cost-UtilityICERUAE Payer
Decision-tree model from the UAE payer view: isavuconazole is dominant versus liposomal amphotericin B (AED 48.6k vs 138.3k; 5.88 vs 5.16 QALYs).
Abstract2025
Cost-Effectiveness Analysis of Isavuconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in United Arab Emirates
Disease area: Invasive Fungal Infections • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
Cost-UtilityICERUAE Payer
Decision-tree model: isavuconazole is cost-effective versus voriconazole at an ICER of AED 1,929 per QALY gained (7.15 vs 6.21 QALYs).
Abstract2025
Cost-Minimization Analysis of Ceftobiprole versus Ceftazidime plus Linezolid for the Treatment of Hospital-Acquired Pneumonia in United Arab Emirates
Disease area: Bacterial Infections • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
Cost-MinimizationAntimicrobialsUAE Payer
Ceftobiprole monotherapy saves about AED 1,123 per patient versus ceftazidime + linezolid, and stays cost-saving across all sensitivity analyses.
Abstract2025
Cost-Minimization Analysis of Delafloxacin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in United Arab Emirates (UAE)
Disease area: Bacterial Infections • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
Cost-MinimizationMRSAUAE Payer
IV-to-oral delafloxacin costs AED 5,867 versus ~AED 12,500 for infusion-based regimens, saving roughly AED 6,600–6,900 per patient.
Abstract2025
Budget Impact Analysis of Cariprazine for the Treatment of Schizophrenia with Predominantly Negative Symptoms in United Arab Emirates (UAE)
Disease area: Schizophrenia • International ISPOR UAE Chapter Conference 2025, Rosewood Abu Dhabi — May 2025
Budget ImpactFormularyPublic Payer
Adding cariprazine to a UAE psychiatric hospital formulary yields a cumulative 5-year saving of about USD 722k, driven by lower resource use.
No publications match these filters.
